ProfileGDS5678 / 1417703_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 70% 69% 69% 74% 67% 70% 70% 69% 69% 75% 74% 70% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.232569
GSM967853U87-EV human glioblastoma xenograft - Control 24.3960870
GSM967854U87-EV human glioblastoma xenograft - Control 34.2163869
GSM967855U87-EV human glioblastoma xenograft - Control 44.3579469
GSM967856U87-EV human glioblastoma xenograft - Control 54.8790874
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1193467
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3780770
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3098670
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2339269
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3201969
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9908475
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8169674
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.380170
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5729872